Evidence map›Paper›PMID 36276483›Full record

ArticleOncology letters2022

Mismatch repair proteins expression and tumor-infiltrating T-cells in colorectal cancer.

Takahiro Shigaki, Kenji Fujiyoshi, Tomoya Sudo, Akihiro Kawahara, Hiroyuki Nakane, Takato Yomoda, Sachiko Nagasu, Tetsushi Kinugasa, Jun Akiba, Fumihiko Fujita and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Takahiro ShigakiDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Kenji FujiyoshiDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Tomoya SudoDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Akihiro KawaharaDepartment of Pathology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Hiroyuki NakaneDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Takato YomodaDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Sachiko NagasuDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Tetsushi KinugasaDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Jun AkibaDepartment of Pathology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Fumihiko FujitaDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Yoshito AkagiDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Kurume University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microsatellite instability (MSI) and tumor mutational burden (TMB) are indicators of the tumor mutational load, which can lead to immune cell recruitment. By contrast, the number of tumor-infiltrating T cells (TITs) is indicative of the host immune response to tumor cells. The present study evaluated if the expression of mismatch repair (MMR) proteins can be used as a precise tool to assess immunogenicity in the tumor microenvironment. A total of 73 colorectal cancer cases were enrolled in the present study. MMR protein expression was assessed using four-antibodies immunohistochemistry (IHC) targeting

Indexed as

antitumor immunitycancer immunotherapyclinical outcomecolorectal carcinoma

Identifiers

PMID36276483
PMCPMC9533364
OpenAlexW4296755147

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.